Compare Barclays PLC (BCS) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Biogen Inc — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Barclays PLC is far larger — about 3.1× Biogen Inc's market cap, and Barclays PLC pays a 2.19% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BCS | BIIB | |
|---|---|---|
Market Cap | $93.87B | $30.13B |
Sector | Financials | Health |
52-Week High | $28.56 | $216.63 |
52-Week Low | $19.36 | $128.93 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $37.20B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
